英诺特(688253) - 2024 Q2 - 季度业绩预告

Financial Performance - For the first half of 2024, the company expects to achieve operating revenue of approximately RMB 421 million, representing a year-on-year growth of about 88.30%[9] - The net profit attributable to shareholders for the first half of 2024 is projected to be around RMB 206 million, reflecting a year-on-year increase of approximately 166.11%[9] - The performance forecast is based on preliminary calculations by the company's financial department and has not yet been audited by registered accountants[15] Market Development - The company benefits from the continuous advancement of the national hierarchical medical system and the increased awareness of early diagnosis and treatment among patients[14] - The company has intensified its efforts in expanding into grade hospitals and grassroots medical markets, contributing to positive market development[14]